Patent SG-11201908894S-A (SG)
Title: Ip6k inhibitors
Inventor: TERAO YOSHITO
IPC: C07D401/12
Filed: 2018-03-29
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT ill 1111u°11111DIVIIl °nolo motions Em Imo oimIE (10) International Publication Number WO 2018/182051 Al (51) International Patent Classification: CO7D 401/12 (2006.01) A61K 31/404 (2006.01) CO7D 209/54 (2006.01) A61P 9/00 (2006.01) (21) International Application Number: PCT/JP2018/014502 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2017-066579 30 March 2017 (30.03.2017) JP (71) Applicant: TAKEDA PHARMACEUTICAL COMPA- NY LIMITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo- ku, Osaka-shi, Osaka, 5410045 (JP). (72) Inventors: TERAO, Yoshito; c/o TAKEDA PHAR- MACEUTICAL COMPANY LIMITED, 26-1, Murao- ka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). TAKAHASHI, Masashi; c/o TAKEDA PHAR- MACEUTICAL COMPANY LIMITED, 26-1, Murao- ka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). HARA, Ryoma; c/o TAKEDA PHARMACEUTI- CAL COMPANY LIMITED, 26-1, Muraoka-Higashi 2- chome, Fujisawa-shi, Kanagawa, 2510012 (JP). HIDAKA, Kousuke; c/o TAKEDA PHARMACEUTICAL COMPA- NY LIMITED, 26-1, Muraoka-Higashi 2-chome, Fuji- sawa-shi, Kanagawa, 2510012 (JP). FURUKAWA, Hode- ki; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). YAMASAKI, Takeski; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). KASAI, Shizuo; c/o TAKEDA PHARMA- CEUTICAL COMPANY LIMITED, 26-1, Muraoka-Hi- gashi 2-chome, Fujisawa-shi, Kanagawa, 2510012 (JP). (74) Agent: TAKASHIMA, Hajime et al.; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410044 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: IP6K INHIBITORS W O 20 18/ 18 205 1 Al (57) : The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for- diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I) : wherein each symbol is as defined in the SPECIFICATION, or a salt OH thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like. (I)